Treatment of Mycobacterium tuberculosis: A Persisting Challenge
A special issue of Antibiotics (ISSN 2079-6382). This special issue belongs to the section "Antibiotic Therapy in Infectious Diseases".
Deadline for manuscript submissions: closed (30 June 2022) | Viewed by 1581
Special Issue Editors
Interests: Infection biology; host–pathogen interactions; tuberculosis; antibiotics; persistence; microfluidics; single-cell imaging; microscopy
Interests: HIV; microbiome; inflammation; immunosenescence; pulmonary infection; ARDS; pulmonary dysfunction; COPD; emphysema
Special Issue Information
Dear Colleagues,
Antibiotics targeting Mycobacterium tuberculosis have been around for more than 75 years now. However, treatment of tuberculosis is extremely challenging and mandates the use of multiple drugs in a strict regimen to effect a successful cure.
The main requisites for a candidate new drug against TB are
- Good cidal activity to be able to rapidly reduce the bacterial population and thereby minimize further transmission;
- (Better?) activity against the bacteria during the persistent phase to ensure quick and complete cure;
- Low frequency of drug resistance.
While there have been several promising new compounds that have been added to the pipeline in the last few decades, we still do not have any compound that specifically targets the persistent phase of M. tuberculosis infection. Targeting persistent subpopulations is extremely crucial if we are to achieve the goal of shortening the duration of TB therapy. Recent advances in single-cell biology and imaging have helped us to gain an understanding of some of the challenges to achieving these goals. This Special Issue seeks manuscript submissions that expand our understanding of the mechanisms M. tuberculosis adopts to survive and persist against antibiotics. Submissions on approaches to identify compounds that can specifically target these persisting subpopulations are especially encouraged.
Dr. Neeraj Dhar
Dr. Shulin Qin
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibiotics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Mycobacterium tuberculosis
- Persistence
- Antibiotics
- TB
- Drug discovery
- Granuloma
- Imaging
